The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience
Asal Ridha,1 Saba Hussein,2 Ali AlJabban,3 Levent Mert Gunay,3 Faiq I Gorial,4 Nizar Abdulateef Al Ani4 1Rheumatology Unit, Department of Medicine, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq; 2Rheumatology Unit, Department of Medicine, Al-Kindy Teaching Hospital, Baghdad, Iraq; 3Medical...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-06-01
|
| Series: | Open Access Rheumatology: Research and Reviews |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-clinical-impact-of-seropositivity-on-treatment-response-in-patient-peer-reviewed-fulltext-article-OARRR |
| _version_ | 1818253392174120960 |
|---|---|
| author | Ridha A Hussein S AlJabban A Gunay LM Gorial FI Al Ani NA |
| author_facet | Ridha A Hussein S AlJabban A Gunay LM Gorial FI Al Ani NA |
| author_sort | Ridha A |
| collection | DOAJ |
| description | Asal Ridha,1 Saba Hussein,2 Ali AlJabban,3 Levent Mert Gunay,3 Faiq I Gorial,4 Nizar Abdulateef Al Ani4 1Rheumatology Unit, Department of Medicine, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq; 2Rheumatology Unit, Department of Medicine, Al-Kindy Teaching Hospital, Baghdad, Iraq; 3Medical Department, Pfizer, Baghdad, Iraq; 4Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, IraqCorrespondence: Ali AlJabban, Medical Department, Pfizer, Building 5, Street 51, Sec. 611, AlDawoodi, Baghdad, Iraq, Tel +964 7706056226, Email aliabdulmohsinabdulkareem.aljabban@pfizer.comPurpose: To assess the clinical impact of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA)’s seropositivity on treatment response in patients with rheumatoid arthritis (RA) treated with etanercept.Patients and Methods: A retrospective analysis of patients with RA registered in Baghdad Teaching Hospital Registry from May 2012 to August 2019 was conducted. Patients aged ≥ 18 years, meeting the ACR/EULAR 2010 criteria for RA, being treated with etanercept, and followed up at ≥ 1 year after etanercept initiation were included; patients who received any other biologics for RA were excluded. Patients were classified as seropositive (RF- and ACPA-positive), seronegative (RF- and ACPA-negative), RF-positive, RF-negative, ACPA-positive, and ACPA-negative. The primary outcomes included Clinical Disease Activity Index (CDAI) and Disease Activity Score 28 (DAS28) which were measured at one year after treatment initiation.Results: At baseline, a total of 1318 (88.3%) patients were seropositive; 1122 (75.2%) and 1054 (70.6%) patients were RF- and ACPA-positive, respectively. Baseline mean CDAI scores were significantly (P = 0.001) higher among seropositive patients compared with seronegative patients. The baseline mean DAS28 score was also significantly higher in ACPA-positive group compared with the ACPA-negative group (P = 0.021). At baseline, the number of patients who had high CDAI scores was significantly higher among the seropositive, RF-positive, and ACPA-positive groups (P = 0.001, P = 0.001, and P = 0.002, respectively). After one year of treatment with etanercept, among seropositive versus seronegative and ACPA-positive versus ACPA-negative groups, there was a significant improvement in terms of the mean CDAI score (P = 0.004 and P = 0.017, respectively) and CDAI response (P = 0.011 and P = 0.048, respectively). At one year, the proportion of patients among the seropositive versus seronegative group who reached remission were 566 (42.9%) versus 78 (44.6%) and 642 (47.3%) versus 83 (47.4%), for CDAI and DAS28 response, respectively.Conclusion: The results imply that seropositivity and ACPA-positivity may influence the treatment response in patients with RA, who were treated with etanercept.Keywords: anti-cyclic citrullinated peptide antibody, Iraq, real-world, rheumatoid factor |
| first_indexed | 2024-12-12T16:39:20Z |
| format | Article |
| id | doaj.art-ad7060bdcefb4312a9b95093e54bb388 |
| institution | Directory Open Access Journal |
| issn | 1179-156X |
| language | English |
| last_indexed | 2024-12-12T16:39:20Z |
| publishDate | 2022-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Open Access Rheumatology: Research and Reviews |
| spelling | doaj.art-ad7060bdcefb4312a9b95093e54bb3882022-12-22T00:18:37ZengDove Medical PressOpen Access Rheumatology: Research and Reviews1179-156X2022-06-01Volume 1411312175940The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi ExperienceRidha AHussein SAlJabban AGunay LMGorial FIAl Ani NAAsal Ridha,1 Saba Hussein,2 Ali AlJabban,3 Levent Mert Gunay,3 Faiq I Gorial,4 Nizar Abdulateef Al Ani4 1Rheumatology Unit, Department of Medicine, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq; 2Rheumatology Unit, Department of Medicine, Al-Kindy Teaching Hospital, Baghdad, Iraq; 3Medical Department, Pfizer, Baghdad, Iraq; 4Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, IraqCorrespondence: Ali AlJabban, Medical Department, Pfizer, Building 5, Street 51, Sec. 611, AlDawoodi, Baghdad, Iraq, Tel +964 7706056226, Email aliabdulmohsinabdulkareem.aljabban@pfizer.comPurpose: To assess the clinical impact of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA)’s seropositivity on treatment response in patients with rheumatoid arthritis (RA) treated with etanercept.Patients and Methods: A retrospective analysis of patients with RA registered in Baghdad Teaching Hospital Registry from May 2012 to August 2019 was conducted. Patients aged ≥ 18 years, meeting the ACR/EULAR 2010 criteria for RA, being treated with etanercept, and followed up at ≥ 1 year after etanercept initiation were included; patients who received any other biologics for RA were excluded. Patients were classified as seropositive (RF- and ACPA-positive), seronegative (RF- and ACPA-negative), RF-positive, RF-negative, ACPA-positive, and ACPA-negative. The primary outcomes included Clinical Disease Activity Index (CDAI) and Disease Activity Score 28 (DAS28) which were measured at one year after treatment initiation.Results: At baseline, a total of 1318 (88.3%) patients were seropositive; 1122 (75.2%) and 1054 (70.6%) patients were RF- and ACPA-positive, respectively. Baseline mean CDAI scores were significantly (P = 0.001) higher among seropositive patients compared with seronegative patients. The baseline mean DAS28 score was also significantly higher in ACPA-positive group compared with the ACPA-negative group (P = 0.021). At baseline, the number of patients who had high CDAI scores was significantly higher among the seropositive, RF-positive, and ACPA-positive groups (P = 0.001, P = 0.001, and P = 0.002, respectively). After one year of treatment with etanercept, among seropositive versus seronegative and ACPA-positive versus ACPA-negative groups, there was a significant improvement in terms of the mean CDAI score (P = 0.004 and P = 0.017, respectively) and CDAI response (P = 0.011 and P = 0.048, respectively). At one year, the proportion of patients among the seropositive versus seronegative group who reached remission were 566 (42.9%) versus 78 (44.6%) and 642 (47.3%) versus 83 (47.4%), for CDAI and DAS28 response, respectively.Conclusion: The results imply that seropositivity and ACPA-positivity may influence the treatment response in patients with RA, who were treated with etanercept.Keywords: anti-cyclic citrullinated peptide antibody, Iraq, real-world, rheumatoid factorhttps://www.dovepress.com/the-clinical-impact-of-seropositivity-on-treatment-response-in-patient-peer-reviewed-fulltext-article-OARRRanti-cyclic citrullinated peptide antibodyiraqreal-worldrheumatoid factor |
| spellingShingle | Ridha A Hussein S AlJabban A Gunay LM Gorial FI Al Ani NA The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience Open Access Rheumatology: Research and Reviews anti-cyclic citrullinated peptide antibody iraq real-world rheumatoid factor |
| title | The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience |
| title_full | The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience |
| title_fullStr | The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience |
| title_full_unstemmed | The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience |
| title_short | The Clinical Impact of Seropositivity on Treatment Response in Patients with Rheumatoid Arthritis Treated with Etanercept: A Real-World Iraqi Experience |
| title_sort | clinical impact of seropositivity on treatment response in patients with rheumatoid arthritis treated with etanercept a real world iraqi experience |
| topic | anti-cyclic citrullinated peptide antibody iraq real-world rheumatoid factor |
| url | https://www.dovepress.com/the-clinical-impact-of-seropositivity-on-treatment-response-in-patient-peer-reviewed-fulltext-article-OARRR |
| work_keys_str_mv | AT ridhaa theclinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT husseins theclinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT aljabbana theclinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT gunaylm theclinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT gorialfi theclinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT alanina theclinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT ridhaa clinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT husseins clinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT aljabbana clinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT gunaylm clinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT gorialfi clinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience AT alanina clinicalimpactofseropositivityontreatmentresponseinpatientswithrheumatoidarthritistreatedwithetanerceptarealworldiraqiexperience |